Lethal, Malignant, Metastatic Struma Ovarii

被引:27
作者
Marcy, Pierre-Yves [1 ]
Thariat, Juliette [2 ]
Benisvy, Danielle [3 ]
Azuar, Pierre [4 ]
机构
[1] Antoine Lacassagne Canc Res Ctr, Dept Head & Neck Imaging, F-06189 Nice 1, France
[2] Antoine Lacassagne Canc Res Ctr, Dept Radiat Therapy, F-06189 Nice 1, France
[3] Antoine Lacassagne Canc Res Ctr, Dept Nucl Med, F-06189 Nice 1, France
[4] Ctr Hosp Grasse, Dept Surg Oncol, Grasse, France
关键词
OF-THE-LITERATURE;
D O I
10.1089/thy.2010.0022
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Struma ovarii (SO) is extremely rare, with less than 200 reported cases in the medical literature. SO is defined by the presence of an ovarian tumor containing thyroid tissue as the predominant cell type. Malignant transformation is rare and lethal cases of SO are even rarer. We report on a patient presenting with left ovarian cystic SO and lethal outcome. Summary: A 45-year-old woman was diagnosed with a follicular variant of papillary carcinoma on laparotomy and left salpingo-oophorectomy. She had persistently elevated serum thyroglobulin following total thyroidectomy + radioiodine and second-look surgery. Imaging scan analysis showed pelvic tumor recurrence and hypervascular liver metastases during follow-up as well as peritoneal carcinomatosis in the pelvis, right abdominal wall, and malignant ascites. The patient died from cachexia at 37 months after diagnosis. Conclusions: Such an aggressive malignant disease and lethal course of SO is rare. Total thyroidectomy is mandatory to exclude a primary thyroid neoplasm and for radioiodine therapy and follow-up. SO may spread to contralateral ovary, pelvic nodes, peritoneum, liver, lungs, and bones through hematogeneous spread, which is different from the dissemination pattern of papillary thyroid carcinomas. Imaging highlights the mixed behavior of this ovarian tumor.
引用
收藏
页码:1037 / 1040
页数:4
相关论文
共 14 条
[1]   Malignant struma ovarii: Two case reports and a review of the literature [J].
Dardik, RB ;
Dardik, M ;
Westra, W ;
Montz, FJ .
GYNECOLOGIC ONCOLOGY, 1999, 73 (03) :447-451
[2]   PROLIFERATIVE AND HISTOLOGICALLY MALIGNANT STRUMA OVARII - A CLINICOPATHOLOGICAL STUDY OF 54 CASES [J].
DEVANEY, K ;
SNYDER, R ;
NORRIS, HJ ;
TAVASSOLI, FA .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1993, 12 (04) :333-343
[3]   Struma ovarii and hyperthyroidism [J].
Dunzendorfer, T ;
deLas Morenas, A ;
Kalir, T ;
Levin, RM .
THYROID, 1999, 9 (05) :499-502
[4]   RET/PTC3 rearrangement and thyroid differentiation gene analysis in a Struma ovarii fortuitously revealed by elevated serum thyroglobulin concentration [J].
Elisei, R ;
Romei, C ;
Castagna, MG ;
Lisi, S ;
Vivaldi, A ;
Faviana, P ;
Marinò, M ;
Ceccarelli, C ;
Pacini, F ;
Pinchera, A .
THYROID, 2005, 15 (12) :1355-1361
[5]  
GRAMER SF, 1979, CANCER, V44, P1715
[6]  
KEMPERS R D, 1970, Annals of Internal Medicine, V72, P883
[7]   Struma Ovarii and Peritoneal Strumosis with Thyrotoxicosis [J].
Kim, Dohee ;
Cho, Hyun-Chul ;
Park, Jin-Wan ;
Lee, Won-Ae ;
Kim, You-Me ;
Chung, Phil-Sang ;
Park, Seok-Gun ;
Ahn, Woong-Sik ;
Han, Sei-Jun ;
Park, Choong-Hak .
THYROID, 2009, 19 (03) :305-308
[8]  
Makni S Krichen, 2005, J Gynecol Obstet Biol Reprod (Paris), V34, P815
[9]  
PARDOMINDAN FJ, 1983, CANCER-AM CANCER SOC, V51, P337, DOI 10.1002/1097-0142(19830115)51:2<337::AID-CNCR2820510229>3.0.CO
[10]  
2-5